NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancerM.R. Mirza, Line Bjørge|Gynecologic Oncology|2024Cited by 12